Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity-based compensation to a new employee. The package includes options to purchase 4,200 shares at an exercise price of $9.75 per share and restricted stock units (RSUs) for 2,100 shares. The grants were made under the company's 2020 Inducement Plan, approved under NYSE Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS) announced that its investigational CD73 inhibitor, quemliclustat, received orphan drug designation from the FDA for pancreatic cancer treatment. The designation provides benefits including tax credits, user fee exemptions, and potential 7-year market exclusivity upon approval.
Phase 1 ARC-8 study results showed promising median overall survival of 15.7 months with quemliclustat-based regimens, surpassing historical chemotherapy benchmarks. The company's Phase 3 PRISM-1 trial, evaluating quemliclustat plus chemotherapy in 610 first-line metastatic pancreatic cancer patients, is expected to complete enrollment by end of 2025.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, has granted equity-based compensation to six new employees. The awards include 54,800 stock options at an exercise price of $8.50 per share and 27,550 restricted stock units (RSUs). These equity grants were made under the company's 2020 Inducement Plan, approved under NYSE Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced new employment inducement grants. The company's Compensation Committee approved equity awards for one new employee, including options to purchase 2,850 shares at $8.63 per share and restricted stock units for 1,450 shares. The grants were made under the company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS) has granted equity-based compensation to three new employees as part of their inducement package. The awards include:
- Stock options to purchase 21,250 shares at an exercise price of $8.53 per share (closing price as of May 8, 2025)
- Restricted stock units (RSUs) totaling 10,650 shares
These equity awards were granted under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08's "inducement exception."
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focusing on cancer therapies, has announced new employment inducement grants. The company's Compensation Committee has approved equity awards for three new employees, including:
- Options to purchase 39,750 shares at $8.11 per share (closing price on April 23, 2025)
- Restricted stock units (RSUs) to acquire 19,950 shares
These equity awards were granted under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08 inducement exception.